Vir Biotechnology, Inc. VIR Grant revenue — Other revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueNotFromContractWithCustomer.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
Grant payments received in advance that are related to future research activities are deferred and recognized as revenue as the required research and development activities are performed. The grant revenue for the three and six months ended June 30, 2026 and 2025 was not material. As of June 30, 2026 and December 31, 2025, the Company had $1.8 million within accrued and other liabilities on its condensed consolidated balance sheet, related to funds to be refunded to the Gates Foundation. The funds related to the $1.8 million liability as of June 30, 2026 is classified within restricted cash and cash equivalents, current on the Company's condensed consolidated balance sheet.
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s grant revenue — other revenue?
- Vir Biotechnology, Inc. (VIR) reported grant revenue — other revenue of $0 in Q2 2026.
- How has Vir Biotechnology, Inc.'s grant revenue — other revenue changed year-over-year?
- Vir Biotechnology, Inc.'s grant revenue — other revenue decreased by 100.0% year-over-year, from $200K to $0.
- What is the long-term trend for Vir Biotechnology, Inc.'s grant revenue — other revenue?
- Over 4 years (2021 to 2025), Vir Biotechnology, Inc.'s grant revenue — other revenue has grown at a -29.8% compound annual growth rate (CAGR), from $8.22M to $2M.
- What does grant revenue — other revenue mean?
- This metric measures the contribution of grant-based funding relative to other non-core revenue streams, such as licensing fees or miscellaneous income not directly tied to customer contracts. It highlights the company's ability to secure specialized research funding as a distinct revenue component compared to other secondary income sources. Investors use this to assess the stability and diversification of the company's non-commercial revenue base.
Ask your AI about Vir Biotechnology, Inc.'s grant revenue — other revenue.
Connect your AI assistant and compare it to peers, right in your chat.
